# Pregabalin Market > Pregabalin Market Research Report: Size, Share, Trend Analysis By Indication (Neuropathic Pain, Fibromyalgia, Epilepsy, Generalized Anxiety Disorder, Restless Leg Syndrome), By Dosage Form (Oral, Injectable, Transdermal), By Distribution Channel (Retail Pharmacies, Hospitals and Clinics, Online Pharmacies), By End-User (Patients, Physicians, Healthcare Professionals) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.36% - **2024:** $ 6.87 Billion - **2025:** $ 7.31 Billion - **2035:** $ 13.54 Billion - **Key Players:** Pfizer Inc (US), Teva Pharmaceutical Industries Ltd (IL), Mylan N.V. (US), Aurobindo Pharma Limited (IN), Lupin Pharmaceuticals, Inc. (US), Sandoz International GmbH (CH), Hikma Pharmaceuticals PLC (GB), Zydus Cadila (IN) **Report ID:** MRFR/HC/39050-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** May 15, 2026 **URL:** https://www.marketresearchfuture.com/reports/pregabalin-market-41097 --- ## Market Summary ## **Pregabalin Market Overview** As per MRFR analysis, the Pregabalin Market Size was estimated at 6.08 (USD Billion) in 2022. The Pregabalin Market Industry is expected to grow from 6.46(USD Billion) in 2023 to 11.25 (USD Billion) by 2032. The Pregabalin Market CAGR (growth rate) is expected to be around 6.36% during the forecast period (2024 - 2032). ### **Key Pregabalin Market Trends Highlighted** The Pregabalin Market is being driven by the rising incidence of neuropathic pain, the development of healthcare infrastructure, and rising awareness about the treatment of neuropathic pain. There is a thrust for the development of new formulations, the search for new markets, and partnerships of pharmaceutical companies and research centers. New trends include mass production of pregabalin generics, the emergence of fixed-dose combinations, and nonprescription medication such as OTC pain relief as options. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Pregabalin Market Drivers** ### Increasing Prevalence of Neurological Conditions The rising incidence of neurological conditions, such as neuropathic pain, epilepsy, and anxiety disorders, is a major driver of the Pregabalin Market Industry. Pregabalin is commonly prescribed for the treatment of these conditions, leading to increased demand for the drug. According to a report by the World Health Organization (WHO), neurological disorders affect approximately 1 billion people worldwide, contributing significantly to the global disease burden. The growing prevalence of these conditions is expected to continue driving the demand for pregabalin in the coming years. ### Growing Geriatric Population The aging population is another key factor driving the Pregabalin Market Industry. As people age, they are more likely to experience neurological conditions that require treatment with pregabalin. Additionally, older adults are more susceptible to nerve damage and chronic pain, which can also be treated with pregabalin. The increasing number of geriatric patients is expected to contribute to the rising demand for pregabalin in the future. ### Expanding Applications in Pain Management Pregabalin is increasingly being used for the treatment of various types of pain, including neuropathic pain, fibromyalgia, and postoperative pain. Its efficacy in reducing pain intensity and improving function has led to its widespread adoption in pain management. Pregabalin's unique mechanism of action, which involves modulating calcium channels in the central nervous system, provides effective pain relief without the risk of addiction or tolerance.The expanding applications of pregabalin in pain management are expected further to drive the growth of the Pregabalin Market Industry. ## **Pregabalin Market Segment Insights** ### **Pregabalin Market Indication Insights  ** The Pregabalin Market exhibited a promising performance and is anticipated to register steady growth during the forecast period. Pregabalin, a medication prescribed for various neurological conditions, is witnessing increasing adoption due to its efficacy in managing neuropathic pain and other related conditions. The market is segmented based on indication, with key segments including neuropathic pain, fibromyalgia, epilepsy, generalized anxiety disorder, and restless legs syndrome. Neuropathic pain, a common type of chronic pain caused by nerve damage, represents a significant segment in the Pregabalin Market.Pregabalin's ability to alleviate neuropathic pain effectively has contributed to its widespread use, driving segment growth. The increasing prevalence of conditions like diabetic neuropathy and postherpetic neuralgia is expected to fuel demand for pregabalin in the coming years. Fibromyalgia, a chronic condition characterized by widespread musculoskeletal pain and tenderness, is another key segment in the Pregabalin Market. Pregabalin's efficacy in reducing pain and improving sleep quality in fibromyalgia patients has led to its adoption as a first-line treatment option.The rising incidence of fibromyalgia is anticipated to bolster segment growth. Epilepsy, a neurological disorder characterized by recurrent seizures, is a growing segment in the Pregabalin Market. Pregabalin's anticonvulsant properties make it an effective treatment for various types of epilepsy, including partial seizures and generalized tonic-clonic seizures. The increasing prevalence of epilepsy and the growing adoption of pregabalin as an adjunctive therapy are expected to drive segment growth. Generalized anxiety disorder (GAD), characterized by excessive worry and anxiety, is also a significant segment in the Pregabalin Market.Pregabalin's anxiolytic effects have demonstrated efficacy in reducing anxiety symptoms in GAD patients. The rising prevalence of anxiety disorders and the growing recognition of pregabalin's efficacy are expected to stimulate segment growth. Restless legs syndrome (RLS), a neurological condition characterized by an irresistible urge to move the legs, is another growing segment in the Pregabalin Market. Pregabalin's ability to alleviate the unpleasant sensations associated with RLS has led to its increasing adoption. The growing awareness of RLS and the availability of effective treatment options like pregabalin are expected to drive segment growth.Overall, the Pregabalin Market is poised for continued growth in the coming years, driven by the increasing prevalence of neurological conditions and the expanding applications of pregabalin. The market is characterized by a competitive landscape, with key players focusing on product innovation and expanding their global presence. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Pregabalin Market Dosage Form Insights  ** The Pregabalin Market segmentation by Dosage Form includes Oral, Injectable, and Transdermal. The Oral segment held a significant market share in 2023 and is projected to continue its dominance throughout the forecast period. The dominance of the Oral segment can be attributed to its convenience of administration and wide availability. Moreover, oral Pregabalin is generally well-tolerated and has a favorable safety profile, making it a preferred choice among healthcare professionals.  The Injectable segment is expected to exhibit a steady growth rate during the forecast period.The growth of this segment can be attributed to the increasing use of Pregabalin for the treatment of acute pain and epilepsy. Injectable Pregabalin provides a rapid onset of action and can be used in patients who are unable to take oral medications. The Transdermal segment is anticipated to witness a moderate growth rate over the forecast period. Transdermal Pregabalin offers sustained release and can be used for the management of chronic pain. However, its limited efficacy and potential skin irritation may hinder its widespread adoption. ### **Pregabalin Market Distribution Channel Insights  ** The distribution channel segment plays a critical role in the Pregabalin Market, shaping market growth and influencing revenue generation. Retail pharmacies hold a significant share of the market, accounting for approximately 36% of the Pregabalin Market revenue in 2023. These pharmacies offer convenience and accessibility to patients, contributing to their dominance in the distribution landscape.  Hospitals and clinics, on the other hand, account for around 30% of the market share, leveraging their established infrastructure and trusted healthcare professional relationships.Online pharmacies are gaining traction, capturing an estimated 25% of the market share in 2023. Their ability to provide competitive pricing, doorstep delivery, and a wide selection of Pregabalin products is driving their growth. The remaining market share is attributed to other distribution channels, including wholesalers and distributors. ### **Pregabalin Market End-User Insights  ** End-users segment the Pregabalin Market into patients, physicians, and healthcare professionals. In 2023, the patient segment accounted for the largest share of the market, at 65.3%. This is due to the increasing prevalence of neuropathic pain, fibromyalgia, and epilepsy, which are the primary indications for pregabalin. The physician segment is expected to grow at the highest CAGR during the forecast period, owing to the rising awareness of pregabalin's efficacy and safety profile among healthcare professionals. The healthcare professionals segment includes pharmacists, nurses, and other healthcare providers who play a crucial role in patient education and medication management. ### **Pregabalin Market Regional Insights  ** Regionally, North America is expected to dominate the Pregabalin Market, with a market share exceeding 2.36 Billion USD in 2023. The dominance of North America can be attributed to the high prevalence of chronic pain conditions, favorable reimbursement policies, and the presence of major pharmaceutical companies. Europe is expected to hold the second-largest market share, followed by APAC, South America, and MEA. The growth in these regions is attributed to the increasing awareness of Pregabalin, expanding healthcare infrastructure, and rising disposable income. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Pregabalin Market Key Players And Competitive Insights** Major players in the Pregabalin Market industry are constantly striving to gain a competitive edge through various strategies such as product innovation, strategic partnerships, and geographical expansion. Leading Pregabalin Market players are investing heavily in research and development to introduce novel formulations and combination therapies that cater to the evolving needs of patients. Additionally, they are focusing on expanding their product portfolios through acquisitions and collaborations to strengthen their market position and cater to a wider range of therapeutic areas. The Pregabalin Market industry is characterized by intense competition, with several established players and emerging companies vying for market share. These players are adopting various strategies to differentiate their products and services, such as offering customized solutions, providing value-added services, and leveraging digital platforms to enhance customer engagement. Pfizer, a leading player in the Pregabalin Market, holds a significant market share and is recognized for its strong brand recognition and extensive product portfolio. The company has a robust pipeline of innovative products in development, which is expected to strengthen its position in the market further.  Pfizer's global presence and established distribution network provide it with a competitive advantage in reaching a wide range of patients. Additionally, the company's commitment to research and development has resulted in the development of novel formulations and combination therapies that meet the evolving needs of patients. GlaxoSmithKline (GSK) is another key player in the Pregabalin Market with a strong presence in various regions. The company's focus on patient-centric solutions and commitment to innovation has contributed to its success in the market.  GSK's diverse product portfolio includes a range of Pregabalin formulations, which cater to the specific needs of patients with different conditions. The company's global reach and established distribution channels enable it to enter into new markets and expand its customer base effectively. Additionally, GSK's strategic partnerships and collaborations with leading healthcare providers further enhance its market position. ### **Key Companies in the Pregabalin Market Include** - Torrent Pharmaceuticals - Reddy's Laboratories - Glenmark Pharmaceuticals - Amneal - **[Lupin](https://www.nps.org.au/assets/medicines/671c0125-71c0-4136-90ad-af9600953b66.pdf)** - Apotex - Teva - Pfizer - Zydus Cadila - Endo Pharmaceuticals - Mylan - Greenstone - Hikma Pharmaceuticals - Sun Pharmaceuticals - Cipla ### Pregabalin Market Industry Developments - **Q2 2024: FDA Approves First Generic Version of Lyrica (Pregabalin) Oral Solution** The FDA approved the first generic version of Lyrica (pregabalin) oral solution, expanding access to this medication for patients with neuropathic pain, fibromyalgia, and epilepsy. This approval is expected to increase competition and lower costs for patients. - **Q1 2024: Pfizer Announces Launch of New Manufacturing Facility for Pregabalin in Ireland** Pfizer opened a new manufacturing facility in Ireland dedicated to the production of pregabalin, aiming to meet growing global demand and ensure supply chain resilience for its Lyrica brand and generic equivalents. - **Q2 2024: Teva Pharmaceutical Launches Generic Pregabalin Capsules in the United States** Teva Pharmaceutical Industries announced the commercial launch of generic pregabalin capsules in the U.S. market following regulatory approval, expanding its portfolio of generic neurological medications. - **Q2 2024: Sun Pharma Receives UK MHRA Approval for Pregabalin Manufacturing Plant** Sun Pharmaceutical Industries received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its new manufacturing plant dedicated to pregabalin, enabling the company to supply the UK and European markets. - **Q1 2024: Mylan and Lupin Announce Strategic Partnership to Co-Develop Pregabalin Extended-Release Formulation** Mylan and Lupin entered a strategic partnership to co-develop and commercialize an extended-release formulation of pregabalin, targeting improved patient compliance and differentiated market positioning. - **Q2 2024: Aurobindo Pharma Receives US FDA Approval for Pregabalin Oral Solution** Aurobindo Pharma received approval from the US FDA to market pregabalin oral solution in the United States, expanding its generic product offerings for neurological disorders. - **Q1 2024: Dr. Reddy’s Laboratories Launches Pregabalin Capsules in Canada** Dr. Reddy’s Laboratories announced the launch of pregabalin capsules in the Canadian market, following Health Canada’s regulatory approval, strengthening its presence in the North American generics market. - **Q2 2024: Pfizer Appoints New Head of Global Neurology Business Unit** Pfizer announced the appointment of a new head for its Global Neurology Business Unit, which oversees the company’s pregabalin (Lyrica) franchise, as part of a broader leadership restructuring. - **Q1 2024: Zydus Lifesciences Receives US FDA Approval for Pregabalin Capsules** Zydus Lifesciences received approval from the US FDA to market pregabalin capsules in the United States, further expanding its generic drug portfolio. - **Q2 2024: Alkem Laboratories Launches Pregabalin Oral Solution in India** Alkem Laboratories launched a new pregabalin oral solution formulation in India, aiming to address unmet needs in pediatric and geriatric patient populations. ## **Pregabalin Market Segmentation Insights** ### **Pregabalin Market Indication Outlook** - [Neuropathic Pain](../../../reports/neuropathic-pain-market-1390) - Fibromyalgia - Epilepsy - Generalized Anxiety Disorder - Restless Leg Syndrome ### **Pregabalin Market Dosage Form Outlook** - Oral - Injectable - Transdermal ### **Pregabalin Market Distribution Channel Outlook** - Retail Pharmacies - Hospitals and Clinics - Online Pharmacies ### **Pregabalin Market End-User Outlook** - Patients - Physicians - Healthcare Professionals ### **Pregabalin Market Regional Outlook** - North America - Europe - South America - Asia-Pacific - Middle East and Africa ## Market Drivers ### Shift Towards Personalized Medicine The trend towards personalized medicine is significantly impacting the Pregabalin Market. As healthcare shifts from a one-size-fits-all approach to more tailored treatment plans, Pregabalin Market is being recognized for its adaptability in managing various conditions. This shift allows for more precise treatment strategies based on individual patient profiles, including genetic factors and comorbidities. The ability to customize treatment regimens enhances the effectiveness of Pregabalin Market, making it a preferred choice among clinicians. Additionally, the integration of pharmacogenomics into clinical practice may lead to improved patient outcomes and satisfaction. As personalized medicine continues to evolve, the Pregabalin Market is poised for growth, driven by the demand for individualized treatment solutions. ### Regulatory Approvals and Market Access The regulatory landscape plays a crucial role in shaping the Pregabalin Market. Recent approvals from health authorities for new indications and formulations of Pregabalin Market have opened new avenues for market expansion. For instance, the approval of Pregabalin Market for the treatment of generalized anxiety disorder has broadened its therapeutic applications. Moreover, streamlined regulatory processes in various regions facilitate quicker market access for Pregabalin Market, allowing manufacturers to respond promptly to market demands. This regulatory support is essential for maintaining a competitive edge in the market. As more healthcare providers gain access to approved Pregabalin Market products, the market is expected to grow, driven by increased availability and acceptance of this medication. ### Advancements in Pharmaceutical Research Innovations in pharmaceutical research and development are significantly influencing the Pregabalin Market. Ongoing studies are exploring new formulations and delivery methods that enhance the efficacy and safety profile of Pregabalin Market. For instance, research into extended-release formulations may improve patient compliance and therapeutic outcomes. Additionally, the exploration of Pregabalin Market's potential applications in treating anxiety disorders and other off-label uses could expand its market reach. The global market for Pregabalin Market is projected to witness a compound annual growth rate (CAGR) of around 5% over the next few years, driven by these advancements. As pharmaceutical companies invest in research, the Pregabalin Market is likely to experience growth fueled by innovative treatment options. ### Growing Awareness and Education Initiatives The Pregabalin Market is experiencing growth due to increased awareness and education initiatives surrounding neuropathic pain and its treatment options. Healthcare professionals are becoming more informed about the benefits of Pregabalin Market, leading to more frequent prescriptions. Additionally, patient education programs are helping individuals recognize symptoms of neuropathic pain, prompting them to seek medical advice. This heightened awareness is crucial, as it encourages timely diagnosis and treatment, ultimately driving demand for Pregabalin Market. Furthermore, organizations dedicated to pain management are actively promoting the use of Pregabalin Market as a first-line treatment, which may further enhance its market presence. As awareness continues to rise, the Pregabalin Market is likely to benefit from a growing patient base. ### Increasing Prevalence of Neurological Disorders The rising incidence of neurological disorders such as epilepsy, fibromyalgia, and neuropathic pain is a primary driver for the Pregabalin Market. As these conditions become more prevalent, the demand for effective treatment options increases. Pregabalin Market, known for its efficacy in managing neuropathic pain and seizures, is gaining traction among healthcare providers. According to recent estimates, the prevalence of neuropathic pain affects approximately 7-10% of the population, indicating a substantial market potential. This growing patient population necessitates the availability of Pregabalin Market, thereby propelling the market forward. Furthermore, as awareness of these disorders increases, more patients are likely to seek treatment, further driving the demand for Pregabalin Market in the market. ## Future Outlook The Pregabalin Market is projected to grow at a 6.36% CAGR from 2025 to 2035, driven by increasing neurological disorders, rising geriatric population, and expanding therapeutic applications. **New opportunities:** - Development of combination therapies to enhance efficacy and patient compliance. - Expansion into emerging markets with tailored pricing strategies. - Investment in digital health platforms for remote patient monitoring and support. By 2035, the Pregabalin Market is expected to solidify its position as a leading segment in the pharmaceutical industry. ## Segment Insights ### By Indication: Neuropathic Pain (Largest) vs. Fibromyalgia (Fastest-Growing) In the Pregabalin Market, the indication segments exhibit varying degrees of market share. Neuropathic Pain holds the largest share, driven by its prevalence and effective management through Pregabalin Market. Other indications like Fibromyalgia, Epilepsy, Generalized Anxiety Disorder, and Restless Legs Syndrome follow, with Fibromyalgia developing a significant foothold as a notable contender. As awareness and treatment options improve, these segments continue to gain market attention. Neuropathic Pain: Dominant vs. Fibromyalgia: Emerging Neuropathic Pain remains the dominant indication in the Pregabalin Market, largely due to its high incidence and successful treatment regimens. This condition not only affects a substantial portion of the population but also showcases Pregabalin Market’s efficacy in alleviating symptoms. On the other hand, Fibromyalgia, characterized by widespread pain and heightened sensitivity, is emerging rapidly. With increasing recognition and a growing patient population, Fibromyalgia is seeing more research and therapeutic focus, positioning it as a vital segment in future market growth. ### By Dosage Form: Oral (Largest) vs. Injectable (Fastest-Growing) In the Pregabalin Market, the dosage form segment is primarily dominated by the Oral formulation, which holds the largest market share. Oral dosage forms are preferred due to their ease of administration and patient compliance, making them a staple in the treatment of conditions addressed by Pregabalin Market, such as neuropathic pain and anxiety disorders. Conversely, the Injectable dosage form, while less widely used, is witnessing substantial growth, particularly in hospital settings, due to its rapid onset and effectiveness in acute situations. Dosage Form: Oral (Dominant) vs. Injectable (Emerging) The Oral dosage form of Pregabalin Market stands out as the dominant choice among patients due to its convenient administration and adherence benefits. It is particularly suited for chronic conditions where daily management is critical. On the other hand, the Injectable form is emerging as a significant alternative, especially in settings requiring immediate therapeutic effects, such as postoperative pain management or severe cases of neuropathic discomfort. As the healthcare sector continues to evolve, the demand for Injectable formulations is projected to grow, driven by advancements in delivery technology and the rising prevalence of conditions requiring fast relief. ### By Distribution Channel: Retail Pharmacies (Largest) vs. Online Pharmacies (Fastest-Growing) In the Pregabalin Market, retail pharmacies hold the largest share in the distribution channel segment, catering to a wide consumer base and providing immediate access to medications. They have established a robust network and are preferred by patients for their convenience and physical presence. Meanwhile, online pharmacies are rapidly gaining traction, presenting a growing market opportunity as they offer the convenience of at-home prescription fills and competitive pricing, thus appealing to a wider demographic. Growth trends indicate a significant shift towards online pharmacies, spurred by the increasing adoption of e-commerce and the rising digital literacy of consumers. Additionally, the ongoing emphasis on convenience and reduced wait times in medication procurement are primary drivers contributing to this segment's expansion. As consumers seek safer and more efficient ways to access prescriptions, online pharmacies are likely to continue their ascent in the market. Retail Pharmacies (Dominant) vs. Online Pharmacies (Emerging) Retail pharmacies dominate the Pregabalin Market due to their widespread availability and established customer trust. Customers prefer them for their familiarity and the personal interaction with pharmacists, which helps in medication management. They often have extensive inventory and provide professional advice, making them a healthcare cornerstone. In contrast, online pharmacies are emerging as a significant player in the distribution landscape. They attract consumers who prioritize convenience, cost-effectiveness, and discretion in purchasing medications. The rise of telemedicine and digital health platforms further propels online pharmacies, as patients increasingly seek accessible and efficient ways to manage their prescriptions. This dynamic is reshaping consumer behaviors and healthcare delivery, indicating a potential shift in preference towards digital solutions. ### By End-User: Patients (Largest) vs. Physicians (Fastest-Growing) In the Pregabalin Market, the patient segment holds the largest share, driven by the growing prevalence of neuropathic pain conditions and anxiety disorders. As more patients are diagnosed and treated with Pregabalin Market, the segment is expected to maintain its dominant position. Physicians closely follow in market significance, as they are instrumental in prescribing Pregabalin Market, thus facilitating its reach to patients who need it most, making this segment integral to patient care and outcome optimization. Patients (Dominant) vs. Healthcare Professionals (Emerging) Patients represent the dominant segment in the Pregabalin Market, chiefly due to a rising number of individuals suffering from conditions treatable by the drug, such as fibromyalgia and neuropathic pain. Their direct demand shapes market dynamics significantly. On the other hand, healthcare professionals are emerging as a crucial cog in the market framework. Their role in educating patients and providing guidance on Pregabalin Market use not only enhances treatment adherence but also fosters a more informed patient base, ultimately contributing to the increased utilization of Pregabalin Market. As they advocate for comprehensive pain management approaches, healthcare professionals are becoming increasingly important, posing promising growth prospects for this segment. ## Regional Market Share Analysis Regionally, North America is expected to dominate the Pregabalin Market, with a market share exceeding 2.36 Billion USD in 2023. The dominance of North America can be attributed to the high prevalence of chronic pain conditions, favorable reimbursement policies, and the presence of major pharmaceutical companies. Europe is expected to hold the second-largest market share, followed by APAC, South America, and MEA. The growth in these regions is attributed to the increasing awareness of Pregabalin Market, expanding healthcare infrastructure, and rising disposable income. ## Competitive Benchmarking Major players in the Pregabalin Market industry are constantly striving to gain a competitive edge through various strategies such as product innovation, strategic partnerships, and geographical expansion. Leading Pregabalin Market players are investing heavily in research and development to introduce novel formulations and combination therapies that cater to the evolving needs of patients. Additionally, they are focusing on expanding their product portfolios through acquisitions and collaborations to strengthen their market position and cater to a wider range of therapeutic areas. The Pregabalin Market industry is characterized by intense competition, with several established players and emerging companies vying for market share. These players are adopting various strategies to differentiate their products and services, such as offering customized solutions, providing value-added services, and leveraging digital platforms to enhance customer engagement. Pfizer, a leading player in the Pregabalin Market, holds a significant market share and is recognized for its strong brand recognition and extensive product portfolio. The company has a robust pipeline of innovative products in development, which is expected to strengthen its position in the market further.  Pfizer's global presence and established distribution network provide it with a competitive advantage in reaching a wide range of patients. Additionally, the company's commitment to research and development has resulted in the development of novel formulations and combination therapies that meet the evolving needs of patients. GlaxoSmithKline (GSK) is another key player in the Pregabalin Market with a strong presence in various regions. The company's focus on patient-centric solutions and commitment to innovation has contributed to its success in the market.  GSK's diverse product portfolio includes a range of Pregabalin Market formulations, which cater to the specific needs of patients with different conditions. The company's global reach and established distribution channels enable it to enter into new markets and expand its customer base effectively. Additionally, GSK's strategic partnerships and collaborations with leading healthcare providers further enhance its market position. ## Recent News & Developments - **Q2 2024: FDA Approves First Generic Version of Lyrica (Pregabalin Market) Oral Solution** The FDA approved the first generic version of Lyrica (pregabalin) oral solution, expanding access to this medication for patients with neuropathic pain, fibromyalgia, and epilepsy. This approval is expected to increase competition and lower costs for patients. - **Q1 2024: Pfizer Announces Launch of New Manufacturing Facility for Pregabalin Market in Ireland** Pfizer opened a new manufacturing facility in Ireland dedicated to the production of pregabalin, aiming to meet growing global demand and ensure supply chain resilience for its Lyrica brand and generic equivalents. - **Q2 2024: Teva Pharmaceutical Launches Generic Pregabalin Market Capsules in the United States** Teva Pharmaceutical Industries announced the commercial launch of generic pregabalin capsules in the U.S. market following regulatory approval, expanding its portfolio of generic neurological medications. - **Q2 2024: Sun Pharma Receives UK MHRA Approval for Pregabalin Market Manufacturing Plant** Sun Pharmaceutical Industries received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its new manufacturing plant dedicated to pregabalin, enabling the company to supply the UK and European markets. - **Q1 2024: Mylan and Lupin Announce Strategic Partnership to Co-Develop Pregabalin Market Extended-Release Formulation** Mylan and Lupin entered a strategic partnership to co-develop and commercialize an extended-release formulation of pregabalin, targeting improved patient compliance and differentiated market positioning. - **Q2 2024: Aurobindo Pharma Receives US FDA Approval for Pregabalin Market Oral Solution** Aurobindo Pharma received approval from the US FDA to market pregabalin oral solution in the United States, expanding its generic product offerings for neurological disorders. - **Q1 2024: Dr. Reddy’s Laboratories Launches Pregabalin Market Capsules in Canada** Dr. Reddy’s Laboratories announced the launch of pregabalin capsules in the Canadian market, following Health Canada’s regulatory approval, strengthening its presence in the North American generics market. - **Q2 2024: Pfizer Appoints New Head of Global Neurology Business Unit** Pfizer announced the appointment of a new head for its Global Neurology Business Unit, which oversees the company’s pregabalin (Lyrica) franchise, as part of a broader leadership restructuring. - **Q1 2024: Zydus Lifesciences Receives US FDA Approval for Pregabalin Market Capsules** Zydus Lifesciences received approval from the US FDA to market pregabalin capsules in the United States, further expanding its generic drug portfolio. - **Q2 2024: Alkem Laboratories Launches Pregabalin Market Oral Solution in India** Alkem Laboratories launched a new pregabalin oral solution formulation in India, aiming to address unmet needs in pediatric and geriatric patient populations. ## Report Scope | MARKET SIZE 2024 | 6.871(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 7.308(USD Billion) | | MARKET SIZE 2035 | 13.54(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.36% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2023 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Pfizer Inc (US), Teva Pharmaceutical Industries Ltd (IL), Mylan N.V. (US), Aurobindo Pharma Limited (IN), Lupin Pharmaceuticals, Inc. (US), Sandoz International GmbH (CH), Hikma Pharmaceuticals PLC (GB), Zydus Cadila (IN) | | Segments Covered | Indication, Dosage Form, Distribution Channel, End-User, Regional | | Key Market Opportunities | Expansion of Pregabalin applications in neuropathic pain management and anxiety disorders presents growth potential. | | Key Market Dynamics | Rising demand for Pregabalin in pain management drives competitive dynamics and regulatory scrutiny in pharmaceutical markets. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the projected market valuation of the Pregabalin Market by 2035?** A: The Pregabalin Market is projected to reach a valuation of 13.54 USD Billion by 2035. **Q: What was the market valuation of the Pregabalin Market in 2024?** A: In 2024, the Pregabalin Market was valued at 6.871 USD Billion. **Q: What is the expected CAGR for the Pregabalin Market during the forecast period 2025 - 2035?** A: The expected CAGR for the Pregabalin Market during the forecast period 2025 - 2035 is 6.36%. **Q: Which companies are considered key players in the Pregabalin Market?** A: Key players in the Pregabalin Market include Pfizer Inc, Teva Pharmaceutical Industries Ltd, Mylan N.V., Aurobindo Pharma Limited, Lupin Pharmaceuticals, Sandoz International GmbH, Hikma Pharmaceuticals PLC, and Zydus Cadila. **Q: What are the main indications for Pregabalin and their market values?** A: The main indications for Pregabalin include Neuropathic Pain (5.0 USD Billion), Fibromyalgia (3.0 USD Billion), Epilepsy (2.0 USD Billion), Generalized Anxiety Disorder (2.5 USD Billion), and Restless Legs Syndrome (1.5 USD Billion) by 2035. **Q: How does the distribution channel impact the Pregabalin Market?** A: By 2035, the distribution channels for Pregabalin are expected to generate revenues of 4.071 USD Billion from Retail Pharmacies, 4.071 USD Billion from Hospitals and Clinics, and 5.398 USD Billion from Online Pharmacies. **Q: What dosage forms are available for Pregabalin and their projected market values?** A: Projected market values for Pregabalin dosage forms by 2035 include Oral (7.0 USD Billion), Injectable (4.0 USD Billion), and Transdermal (2.54 USD Billion). **Q: Who are the primary end-users of Pregabalin?** A: Primary end-users of Pregabalin include Patients (4.217 USD Billion), Physicians (4.217 USD Billion), and Healthcare Professionals (5.106 USD Billion) by 2035. **Q: What trends are influencing the growth of the Pregabalin Market?** A: The growth of the Pregabalin Market appears to be influenced by increasing prevalence of neurological disorders and expanding therapeutic applications. **Q: How does the Pregabalin Market compare to other pharmaceutical markets?** A: The Pregabalin Market, with a valuation of 6.871 USD Billion in 2024, indicates a robust growth trajectory compared to other pharmaceutical markets, particularly with its projected growth to 13.54 USD Billion by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/pregabalin-market-41097*